Skip to main content
Dec 12, 2024

People moves: Wynn Resorts shuffles the IR deck with two new appointments

Other IR changes at Onity Group, Karyopharm Therapeutics, Altron Group and Biogen

Wynn Resorts, the Nasdaq-listed hotel and casino operator, has announced two changes to its investor relations team with Price Karr, currently its senior vice president of corporate finance and treasurer, taking on the role of senior vice president of IR.

Karr originally joined the company in 2008 before spending several years on the sell side, including at Goldman Sachs where he was vice president in the real estate, gaming and lodging investment banking team. He rejoined Wynn in his current role in 2023.

At the same time, Wynn has brought in Lauren Seiler as vice president of IR, reporting to Karr. Most recently, she was CEO and founder at consulting firm Global Gaming Advisors. Prior to that, she ran IR and corporate development at Rush Street Interactive.

‘I am pleased that Price is taking on this important additional responsibility and we welcome Lauren to bolster our investor relations program,’ says Julie Cameron-Doe, Wynn’s CFO.

‘Price has consistently proven himself to be adept at communicating Wynn Resorts’ strategy and compelling opportunities to our investor base. Lauren will be an excellent complement to Price, bringing deep industry knowledge, fresh perspectives and a track record of enhancing relationships with the investment community through clear, consistent and transparent communications.’

Elsewhere, Onity Group, the non-bank mortgage provider, has named Valerie Haertel as vice president of IR. Haertel has extensive experience leading IR teams at major corporations, including Vestis, CVS Health, BNY Mellon, State Street Corporation and AllianceBernstein. She also served as NIRI national chair between 2017 and 2018.

‘We are excited to welcome Valerie to lead investor relations at Onity,’ says Sean O’Neil, the company’s CFO, in a statement. ‘Her extensive experience in building and enhancing investor relations and external communications programs and strong relationships within the investment community will be invaluable to the communication of our strategic priorities and the factors that drive our financial results to create value for our shareholders.’

Karyopharm Therapeutics, the Nasdaq-listed pharmaceutical company focused on cancer therapies, has appointed Brendan Strong as senior vice president of IR and corporate communications.

Most recently, Strong worked as managing director at Argot Partners, where he advised companies on their IR and communications efforts. He has also led IR at Tenet Healthcare and prior to that worked on the sell side at Barclays and Lehman Brothers.

‘We are thrilled to have Brendan on board as we work towards delivering on and communicating important milestones for our organization in 2025,’ says Richard Paulson, president and CEO at Karyopharm Therapeutics.

‘Brendan's experience as a former sell-side analyst, advisor to biopharmaceutical companies and proven ability to develop strong investor relations and corporate communications programs will serve us well as we look to execute on the opportunities ahead of us.’

In other people news, Zanele Salman will become executive of IR at South African tech firm Altron Group, with the role effective in February next year. Salman has two decades of experience across business development, marketing and IR, taking in positions at companies including AECI Limited, Sasol Limited and Nampak Limited.

In a press release, Altron’s CEO Werner Kapp said the appointment would bring ‘extensive industry experience’ to the technology group.

Finally, Biogen, the Nasdaq-listed biotechnology company, has appointed Tim Power as vice president and head of IR. Previously, Power served as vice president and head of IR at Bristol Myers Squibb. In total, he has more than two decades of experience across finance and investor relations roles.

‘I am delighted to welcome Tim to Biogen,’ says Michael McDonnell, the firm’s CFO, in a statement. ‘His exceptional expertise in investor relations and ability to communicate complex business strategies, coupled with his strong background in articulating breakthrough scientific advancements, will be invaluable as we continue to work toward our goal of returning to sustainable growth.’

Clicky